Minimal Extrathyroidal Extension Does Not Predict Initial Treatment Response, but Is a Better Prognostic Factor when Combined with Tumor Size

2021 ◽  
Vol 33 (11) ◽  
pp. 493-496
Author(s):  
Tyler Drake
Thyroid ◽  
2018 ◽  
Vol 28 (8) ◽  
pp. 982-990 ◽  
Author(s):  
Samantha Tam ◽  
Moran Amit ◽  
Mongkol Boonsripitayanon ◽  
Naifa L. Busaidy ◽  
Maria E. Cabanillas ◽  
...  

2017 ◽  
Vol 24 (5) ◽  
pp. 221-226 ◽  
Author(s):  
Zaid Al-Qurayshi ◽  
Mohamed A Shama ◽  
Gregory W Randolph ◽  
Emad Kandil

Differentiated thyroid cancer (DTC) with minimal extrathyroidal extension (MEE) is classified as stage III regardless of the tumor size. In this study, we aim to examine the effect of MEE on the overall survival and management of this population. A retrospective cohort study was performed, which utilized the National Cancer Database (NCDB), 2004–2012. The study population included patients, aged ≥ 45 years, who underwent surgery for DTC (pT3N0M0) with MEE compared to that in patients with pT2N0M0. A total of 9556 patients were included. These were divided into four groups, 4410 patients with pT2N0M0 (Group 1: T ≤ 4 cm without MEE), 3274 with pT3N0M0 (Group 2: T ≤ 4 cm with MEE), 447 with pT3N0M0 (Group 3: T > 4 cm with MEE) and 1430 patients with pT3N0M0 without MEE (Group 4: T > 4 cm without MEE). Median follow-up time was 46.7 months (interquartile range: 27.8–72.1). Patients in Group 2 (T ≤ 4 cm with MEE) had no significant worse survival compared to patients in Group 1 (T ≤ 4 cm without MEE) (P = 0.85), whereas Groups 3 and 4 (T > 4 cm), both had significantly lower survival (P < 0.001) with no difference between the two groups. Total thyroidectomy was associated with improved overall survival compared to that in lobectomy in Group 4 (T > 4 cm without MEE). Radioiodine utilization was associated with improved survival only with tumors larger than 4 cm with or without MEE. In DTC patients aged older than 45 years of age with tumor size less than 4 cm, MEE has no survival significance. Tumor size is an independent prognostic marker regardless of MEE status. Our data support re-evaluation of the current staging system.


2013 ◽  
Vol 11 (9) ◽  
pp. 944-947 ◽  
Author(s):  
Jae Ho Shin ◽  
Tae Kwun Ha ◽  
Ha Kyoung Park ◽  
Min Sung Ahn ◽  
Kwang Hee Kim ◽  
...  

2020 ◽  
Vol 220 (4) ◽  
pp. 925-931
Author(s):  
Chol-Ho Shin ◽  
Jong-Lyel Roh ◽  
Dong Eun Song ◽  
Kyung-Ja Cho ◽  
Seung-Ho Choi ◽  
...  

2021 ◽  
Vol 12 ◽  
Author(s):  
Tian-han Zhou ◽  
Bei Lin ◽  
Fan Wu ◽  
Kai-ning Lu ◽  
Lin-lin Mao ◽  
...  

PurposeTo investigate the prognostic significance of extranodal extension (ENE) in papillary thyroid cancer (PTC).MethodsSeven hundred forty-three PTC patients were enrolled in the study from January 2014 to December 2017. The patients were dichotomized according to the presence of ENE. Logistic analysis was used to compare differences between the two groups. Kaplan–Meier (K-M) curve and propensity score matching (PSM) analyses were used for recurrence-free survival (RFS) comparisons. Cox regression was performed to analyze the effects of ENE on RFS in PTC.ResultsThirty-four patients (4.58%) had ENE. Univariate analysis showed that age, tumor size, extrathyroidal extension, and nodal stage were associated with ENE. Further logistic regression analysis showed that age, extrathyroidal extension, and nodal stage remained statistically significant. Evaluation of K-M curves showed a statistically significant difference between the two groups before and after PSM. Cox regression showed that tumor size and ENE were independent risk factors for RFS.ConclusionsAge ≥55 years, extrathyroidal extension, and lateral cervical lymph node metastasis were identified as independent risk factors for ENE. ENE is an independent prognostic factor in PTC.


2012 ◽  
Vol 53 (2) ◽  
pp. 326-332 ◽  
Author(s):  
Hiroshi OKADA ◽  
Shigeto HONTSU ◽  
Sachiko MIURA ◽  
Isao ASAKAWA ◽  
Tetsuro TAMAMOTO ◽  
...  

2010 ◽  
Vol 45 (4) ◽  
pp. 457-467 ◽  
Author(s):  
Mårten Werner ◽  
Sven Wallerstedt ◽  
Stefan Lindgren ◽  
Sven Almer ◽  
Einar Björnsson ◽  
...  

2014 ◽  
Vol 138 (8) ◽  
pp. 1048-1052 ◽  
Author(s):  
Arnold M. Schwartz ◽  
Donald Earl Henson ◽  
Dechang Chen ◽  
Sivasankari Rajamarthandan

Context.—The appropriate staging of breast cancers includes an evaluation of tumor size and nodal status. Histologic grade in breast cancer, though important and assessed for all tumors, is not integrated within tumor staging. Objective.—To determine whether the histologic grade remains a prognostic factor for breast cancer regardless of tumor size and the number of involved axillary lymph nodes. Design.—By using a new clustering algorithm, the 10-year survival for every combination of T, N, and the histologic grade was determined for cases of breast cancer obtained from the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute. There were 36 combinations of TN, defined according to the American Joint Committee on Cancer, and grade. Results.—For each combination of T and N, a categorical increase in the histologic grade was associated with a progressive decrease in 10-year survival regardless of the number of involved axillary lymph nodes or size of the primary tumor. Absolute survival differences between high and low grade persisted despite larger tumor sizes and greater nodal involvement, though trends were apparent with increasing breast cancer stage. Statistical significance depended on the number of cases for each combination. Conclusions.—Histologic grade continues to be of prognostic importance for overall survival despite tumor size and nodal status. Furthermore, these results seem to indicate that the assignment of the histologic grade has been consistent among pathologists when evaluated in a large data set of patients with breast cancer. The incorporation of histologic grade in TNM staging for breast cancer provides important prognostic information.


Sign in / Sign up

Export Citation Format

Share Document